Alopecia areata (AA) is a recurring autoimmune disease that can have a devastating physical and emotional impact. This is not simply a cosmetic issue. While there are currently no FDA-approved treatments available for patients with AA, there are treatments on the horizon that give hope to patients.

Recorded on Wednesday, May 26, 2021, this webinar features a discussion on the changing treatment landscape and the considerations for patients, providers, and payers on the path toward treatment.

Xcenda's Jennifer Snow, MPH, Vice President, Reimbursement and Policy Insights, moderated this panel discussion featuring the following panelists:

• Dr. Brett King, MD, PhD, Yale Medicine
• Leslie Stein Lloyd, JD, IOM, CAE, Director, Public Policy and Healthcare Economics, American Academy of Dermatology Association
• Kate Hanni, Chief Development Strategist, National Alopecia Areata Foundation